📊 SEPN Key Takeaways
Is Septerna, Inc. (SEPN) a Good Investment?
Septerna demonstrates exceptional revenue growth (4,174% YoY) suggesting successful product commercialization, but faces severe profitability challenges with negative operating margins (-50.1%) and negative operating cash flow (-$25.6M), indicating the business is not sustainable at current cost structures despite solid balance sheet reserves.
Septerna, Inc. Key Strengths (SEPN)
- Extraordinary revenue growth of 4,174% YoY demonstrates strong market traction and successful product commercialization
- Fortress balance sheet with zero long-term debt, $71.6M cash, and 4.71x current ratio providing substantial runway
- Improving EPS trajectory (+84.8% YoY) suggesting margin compression is narrowing
SEPN Stock Risks: Septerna, Inc. Investment Risks
- Severely negative operating cash flow (-$25.6M) against only $26.5M revenue indicates unsustainable burn rate and operational inefficiency
- Operating losses of $13.3M on $26.5M revenue (-50.1% margin) suggests structural cost challenges with manufacturing/operations
- Path to profitability unclear in highly competitive pharmaceutical sector; company must demonstrate ability to scale efficiently and achieve positive operating leverage
Key Metrics to Watch
- Operating cash flow trajectory and path to cash flow breakeven
- Gross margin percentage and operating leverage improvements as revenue scales
- Cash runway duration given current burn rate and funding sustainability
Septerna, Inc. (SEPN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.71x current ratio provides a solid financial cushion.
SEPN Profit Margin, ROE & Profitability Analysis
SEPN vs Healthcare Sector: How Septerna, Inc. Compares
How Septerna, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Septerna, Inc. Stock Overvalued? SEPN Valuation Analysis 2026
Based on fundamental analysis, Septerna, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Septerna, Inc. Balance Sheet: SEPN Debt, Cash & Liquidity
SEPN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Septerna, Inc.'s revenue has grown significantly by 4,175% over the 5-year period, indicating strong business expansion. The most recent EPS of $-7.26 indicates the company is currently unprofitable.
SEPN Revenue Growth, EPS Growth & YoY Performance
SEPN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $219.0K | -$8.6M | $-0.19 |
| Q3 2025 | $176.0K | $8.2M | $0.18 |
| Q2 2025 | $119.0K | -$14.2M | $-0.56 |
| Q1 2025 | $219.0K | -$14.2M | $-0.49 |
| Q3 2024 | $33.0K | -$9.2M | $-5.45 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Septerna, Inc. Dividends, Buybacks & Capital Allocation
SEPN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Septerna, Inc. (CIK: 0001984086)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SEPN
What is the AI rating for SEPN?
Septerna, Inc. (SEPN) has an AI grade of C with 65% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SEPN's key strengths?
Claude: Extraordinary revenue growth of 4,174% YoY demonstrates strong market traction and successful product commercialization. Fortress balance sheet with zero long-term debt, $71.6M cash, and 4.71x current ratio providing substantial runway.
What are the risks of investing in SEPN?
Claude: Severely negative operating cash flow (-$25.6M) against only $26.5M revenue indicates unsustainable burn rate and operational inefficiency. Operating losses of $13.3M on $26.5M revenue (-50.1% margin) suggests structural cost challenges with manufacturing/operations.
What is SEPN's revenue and growth?
Septerna, Inc. reported revenue of $26.5M.
Does SEPN pay dividends?
Septerna, Inc. does not currently pay dividends.
Where can I find SEPN SEC filings?
Official SEC filings for Septerna, Inc. (CIK: 0001984086) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SEPN's EPS?
Septerna, Inc. has a diluted EPS of $-0.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is SEPN's fundamental grade?
Based on our AI fundamental analysis in June 2026, Septerna, Inc. has a C grade with 65% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is SEPN stock overvalued or undervalued?
Valuation metrics for SEPN: ROE of -2.3% (sector avg: 15%), net margin of -32.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is SEPN's AI grade for 2026?
Our dual AI analysis gives Septerna, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SEPN's free cash flow?
Septerna, Inc.'s operating cash flow is $-25.6M, with capital expenditures of $832.0K. FCF margin is -99.8%.
How does SEPN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -32.6% (avg: 12%), ROE -2.3% (avg: 15%), current ratio 4.71 (avg: 2).